The Judicial Panel on Multidistrict Litigation (JPML) is expected to consider creating an MDL for the Zantac litigation at its upcoming hearing in early December. Considering that Zantac (ranitidine) has been on the market for decades and was so widely-used, the number of potential claimants is expected to be significant. Contrary to the recent FDA […]